Currently, patients with advanced and metastatic BC, often presenting HER2 enrichment or TNBC phenotypes, undergo a neoadjuvant regimen, consisting of chemo- or endocrine therapy followed by surgical tumor removal, to prevent spread of metastasis [11]. The gene discussed is ERBB2; the disease is neoplasm.